Ambrx Biopharma Cayman, Inc. Quarterly Contract with Customer, Liability, Noncurrent in USD from Q4 2019 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
Summary
Ambrx Biopharma Cayman, Inc. quarterly Contract with Customer, Liability, Noncurrent history and growth rate from Q4 2019 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Contract with Customer, Liability, Noncurrent for the quarter ending June 30, 2023 was $1.75M, a 58.8% decline year-over-year.
Contract with Customer, Liability, Noncurrent, Quarterly (USD)
Contract with Customer, Liability, Noncurrent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2023 $1.75M -$2.5M -58.8% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $1.75M Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $1.75M -$3.9M -69% Dec 31, 2022 10-Q 2023-08-09
Q2 2022 $4.25M Jun 30, 2022 6-K 2022-08-29
Q4 2021 $5.65M -$4.08M -42% Dec 31, 2021 10-K 2023-03-30
Q4 2020 $9.73M -$1.28M -11.6% Dec 31, 2020 6-K 2022-08-29
Q4 2019 $11M Dec 31, 2019 20-F 2022-04-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.